Key result
Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation currently relies on retrospective data and a Heart Team approach due to a lack of randomized trials.
Why the study?
Randomised controlled trials evaluating the management of CAD in patients undergoing TAVI are lacking, leaving recommendations largely based on retrospective cohort studies.
This review highlights the importance of a Heart Team approach for managing concurrent coronary artery disease in elderly patients undergoing TAVI for severe aortic stenosis.
Concomitant CAD screening in elderly AS patients may inform TAVR planning; leaves open whether revascularization alters outcomes.
Aortic valve stenosis (AS) is the most common valvular heart disease among elderly patients. Since the pathophysiology of degenerative AS shares common pathways with atherosclerotic disease, the severity of AS in the elderly population is often concurrent to the presence of coronary artery disease (CAD). Although surgical aortic valve replacement has been the standard treatment for severe AS, the high operative morbidity and mortality in complex and fragile patients was the trigger to develop less invasive techniques. Transcatheter aortic valve implantation (TAVI) has been posed as the standard of care for elderly patients with severe AS with various risk profiles, which has meant that the concomitant management of CAD has become a crucial issue in such patients. Given the lack of randomised controlled trials evaluating the management of CAD in TAVI patients, most of the recommendations are based on retrospective cohort studies so that the Heart Team approach - together with an assessment of multiple parameters including symptoms and clinical characteristics, invasive and non-invasive ischaemic burden and anatomy - are crucial for the proper management of these patients. This article provides a review of current knowledge about assessment and therapeutic approaches for CAD and severe AS in patients undergoing TAVI.
No takes yet. Share an insight, caveat, or question.
Filho et al. (2021) conducted a review in Coronary artery disease and severe aortic stenosis. Management of coronary artery disease during transcatheter aortic valve implantation was evaluated. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation currently relies on retrospective data and a Heart Team approach due to a lack of randomized trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: